You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Agilent and CRO PureHoney will develop new applications for the RapidFire 365 system, including workflows for pharmaceutical research, forensics, and metabolomics.
Teneovita will distribute Biocept's test services to hospitals, oncology centers, and individual medical practices throughout the country.
CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.
Under the terms of the agreement, M3 and G-TAC will promote 14 Pathway tests through G-TAC's personalized medicine platform connected to M3's physician network.
Under the agreement, Genomic Health will make an undisclosed equity investment in Epic Sciences, and will have exclusive rights to market its test in the US.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
The deal gives SouthGenetics marketing rights for MDxHealth's ConfirmMDx test for prostate cancer in 12 countries, including Mexico, Argentina, and Colombia.
The deal will provide researchers a fully automated solution for immunostaining captured circulating tumor cells deposited on microscope slides.
The deal provides customers a complete end-to-end solution for cytogenomic array and next-generation sequencing services, the firms said.
The partners will co-market the Phenomenex Strata and Strata-X SPE sorbents adapted to Tecan's Freedom EVO series of robotic workstations.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.